What this study is
RADIANT is a network of 14 clinical sites and several laboratories dedicated to the study of atypical diabetes.
The objective of this study is to define new forms of diabetes and the unique mechanisms underlying these forms of atypical diabetes. The specific aims are to:
1. Identify and enroll individuals and families with undiagnosed rare and atypical forms of diabetes. 2. Determine the etiologic basis of the metabolic disorder among individuals and families with novel forms of rare and atypical diabetes. 3. Understand the pathophysiology of individuals and families with novel forms of rare and atypical forms of diabetes.
Study details
- Sponsor
- University of South Florida
- Conditions
- Diabetes Mellitus · Diabetes Mellitus Progression · Glucose Intolerance · Glucose Metabolism Disorders · Metabolic Disease · Endocrine; Complications · Endocrine System Diseases
- Enrolling
- 2,000 people
- Starts
- 2020-09-30
- Est. completion
- 2030-09
- Record
- View on ClinicalTrials.gov ↗
Who can join
Sex ALLHealthy volunteers Not acceptedYou may qualify if
- Type 2 diabetes diagnosed at a time when the individual was prepubertal or non-obese
- Mendelian pattern, especially with early onset (<18 years old)
- Syndromic (multiple systems involved)
- Lipodystrophic
- Extremes of BMI
- "Mitochondrial" characteristics (e.g., myopathy, hearing deficits)
- Non-progressive
- Rapidly progressive ("fulminant")
- Low insulin requirements (<0.5 u/kg/day)
- Cyclical hyperglycemia with periods of remission
- Lean persons with polycystic ovarian syndrome (PCOS)
- History of gestational diabetes (GDM) when lean
- Lean insulin-resistant persons
- If islet autoantibodies and beta-cell function parameters have been measured (where "A" = islet cell autoantibodies, "B" = beta-cell function): oA-B- (i.e., lacking islet autoimmunity makers and lacking beta cell function) oA-B+ with unprovoked DKA at initial presentation (i.e., lacking islet autoimmune markers, with preserved beta-cell function, but presenting with unprovoked DKA) oA-B+ of very young onset (pre-pubertal) (i.e., lacking islet autoimmune markers, with preserved beta-cell function, but very early onset T2D-like phenotype)
You can't join if
- Those with high likelihood of typical type 1, typical type 2, known monogenic, or other known secondary forms of diabetes
- Refusal of consent for genetic testing
- Islet autoantibody positive (participants who are islet autoantibody positive but present with additional atypical features i.e. syndromic, strong linear family history of diabetes may not be excluded)
- Women who are currently pregnant
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (13)
13 openUniversity of Colorado- Denver
Aurora, Colorado, United States
- Marjan Rezaei · Contact303-724-1290marjan.rezaei@cuanschutz.edu
- Neda Rasouli, MD · Principal investigator
RecruitingUniversity of Chicago
Chicago, Illinois, United States
- Lisa Letourneau · Contact773-702-0829radiant@uchicago.edu
- Lou Philipson, MD, PhD · Principal investigator
- Siri Greeley, MD, PhD · Principal investigator
RecruitingIndiana University
Indianapolis, Indiana, United States
- Sarah Fischer · Contact317-278-7042hollowas@iu.edu
- Carmella Evans-Molina, MD, PhD · Principal investigator
RecruitingUniversity of Maryland
Baltimore, Maryland, United States
- Cindi Young · Contact410-979-4322cyoung2@som.umaryland.edu
- Toni Pollin, PhD, MS · Principal investigator
RecruitingMassachusetts General Hospital (MGH)
Boston, Massachusetts, United States
- Julia Douvas · Contact617-724-3954MGHRADIANTStudy@partners.org
- Sara Cromer, MD · Principal investigator
RecruitingUniversity of Michigan
Ann Arbor, Michigan, United States
- Adam Neidert · Contact734-615-0539aneidert@med.umich.edu
- Elif Oral, MD · Principal investigator
RecruitingWashington University in St. Louis
St Louis, Missouri, United States
- Stacy Hurst · Contact314-747-3294shurst@wustl.edu
- Brittany Zsijack · Contact314-747-8251bzwijack@wustl.edu
- Fumihiko Urano, MD, PhD · Principal investigator
RecruitingSUNY Downstate Health Sciences University
Brooklyn, New York, United States
- Necole Brown · Contact718-270-4693necole.brown01@downstate.edu
- Mary Ann Banerji, MD · Principal investigator
RecruitingColumbia University
New York, New York, United States
- Kaisha Mofford · Contact212-851-5512berrietrials@cumc.columbia.edu
- Robin Goland, MD · Principal investigator
RecruitingUniversity of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
- Rachel Unger · Contact984-974-3011RADIANT@med.unc.edu
- John Buse, MD, PhD · Principal investigator
RecruitingVanderbilt University
Nashville, Tennessee, United States
- Norma Edwards · Contact615-403-8937radiant@vumc.org
- Kevin Niswender, MD, PhD · Principal investigator
RecruitingBaylor College of Medicine
Houston, Texas, United States
- Molly Wahlquist · Contact791-798-5757radiantstudy@bcm.edu
- Ashok Balasubramanyam, MD · Principal investigator
- Maria Redondo, MD, PhD, MPH · Principal investigator
RecruitingUniversity of Washington
Seattle, Washington, United States
- Dori Khakpour · Contact206-616-1354dorik@uw.edu
- Irl B Hirsch, MD · Principal investigator
Recruiting
Study team
Sponsor
University of South Florida
Study ID RADIANT
Study chair
Jeffrey Krischer, PhD
University of South Florida
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.